TAK - Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited

1-1, Nihonbashi-Honcho 2-chome
Chuo-ku
Tokyo 103-8668
Japan
81 3 3278 2111
https://www.takeda.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Christophe Weber	Pres, CEO & Representative Director	4.24M	N/A	1966
Mr. Constantine Saroukos	CFO & Representative Director	2.54M	N/A	1971
Dr. Andrew S. Plump	Pres of R&D and Representative Director	2.41M	N/A	1965
Dr. Seigo Izumo	Chair of Management Board	N/A	N/A	N/A
Mr. Haruhiko Hirate	Member of Management Board	N/A	N/A	1957
Salvatore Alesci	Member of Management Board and Head of R&D Global Science & Biomedical Policy	N/A	N/A	N/A
Norimasa Takeda	Chief Accounting Officer & Corp. Controller	N/A	N/A	N/A
Mr. Iwaaki Taniguchi	Sr. VP of Corp. Fin. & Controlling Department	N/A	N/A	N/A
Mr. Gabriele Ricci	Chief Data & Technology Officer	N/A	N/A	1978
Mr. Christopher David O'Reilly	Global Head of Investor Relations & Global Fin.	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Corporate governance

Takeda Pharmaceutical Company Limited’s ISS governance QualityScore as of 1 June 2023 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 9; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.